Cutera, Inc. (NASDAQ:CUTR) has earned a consensus rating of “Hold” from the nine analysts that are currently covering the company, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and two have issued a buy rating on the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $34.65.
A number of equities analysts have recently commented on the stock. Zacks Investment Research lowered shares of Cutera from a “hold” rating to a “sell” rating in a research report on Monday, June 18th. BidaskClub lowered shares of Cutera from a “strong-buy” rating to a “buy” rating in a research report on Friday, July 27th. Stifel Nicolaus reduced their target price on shares of Cutera from $55.00 to $45.00 and set a “hold” rating on the stock in a research report on Wednesday, August 8th. ValuEngine lowered shares of Cutera from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, August 8th. Finally, Stephens reduced their target price on shares of Cutera from $40.00 to $24.94 and set a “sell” rating on the stock in a research report on Friday.
Shares of NASDAQ CUTR opened at $22.02 on Friday. The stock has a market capitalization of $450.39 million, a price-to-earnings ratio of 28.60 and a beta of 0.31. Cutera has a 1 year low of $21.86 and a 1 year high of $56.05.
Cutera (NASDAQ:CUTR) last issued its earnings results on Tuesday, August 7th. The medical device company reported $0.12 EPS for the quarter, missing the Zacks’ consensus estimate of $0.18 by ($0.06). The company had revenue of $42.55 million for the quarter, compared to analysts’ expectations of $41.50 million. Cutera had a return on equity of 10.21% and a net margin of 15.67%. On average, equities analysts forecast that Cutera will post -0.16 EPS for the current year.
In related news, insider James A. Reinstein bought 1,000 shares of Cutera stock in a transaction dated Wednesday, August 29th. The shares were acquired at an average cost of $32.02 per share, with a total value of $32,020.00. Following the completion of the transaction, the insider now owns 139,907 shares in the company, valued at approximately $4,479,822.14. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Company insiders own 1.80% of the company’s stock.
Hedge funds have recently modified their holdings of the stock. Piedmont Investment Advisors LLC purchased a new position in Cutera during the second quarter valued at approximately $128,000. SG Americas Securities LLC purchased a new position in Cutera during the second quarter valued at approximately $154,000. United Services Automobile Association purchased a new position in Cutera during the second quarter valued at approximately $208,000. Ladenburg Thalmann Financial Services Inc. increased its holdings in Cutera by 51.4% during the first quarter. Ladenburg Thalmann Financial Services Inc. now owns 5,300 shares of the medical device company’s stock valued at $266,000 after buying an additional 1,800 shares during the period. Finally, Dynamic Technology Lab Private Ltd purchased a new position in Cutera during the first quarter valued at approximately $296,000. 93.36% of the stock is currently owned by institutional investors.
Cutera, Inc, a medical device company, designs, develops, manufactures, markets, and services laser and other energy based aesthetics systems worldwide. The company offers enlighten platform, a laser system that is used for tattoo removal, as well as for the treatment of benign pigmented lesions; excel HR platform, a hair removal solution for various skin types; and truSculpt, a high-powered radio frequency platform designed for deep tissue heating.
Read More: What does relative strength index mean?
Receive News & Ratings for Cutera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cutera and related companies with MarketBeat.com's FREE daily email newsletter.